Aspire Biopharma Holdings, Inc. has designated 25,000 shares of its authorized stock as Series A Convertible Preferred Stock, effective February 2, 2026, allowing conversion at 80% of the lowest closing price over the preceding five trading days. This move is significant for investors as it affects the company's capital structure and potentially its stock valuation.